Advertisement

Early market access for unauthorized drugs in Italy: The value-based price for reimbursement decisions

Published:February 03, 2016DOI:https://doi.org/10.1016/j.ejim.2016.01.013
      A major challenge for regulatory agencies is balancing the need for rapid access to drugs for new indications against the limited information on their benefit–risk ratio. The processes described by Martinalbo and colleagues depicted a European scenario with different national frameworks [
      • Martinalbo J.
      • Bowen D.
      • Camarero J.
      • Chapelin M.
      • Démolis P.
      • Foggi P.
      • et al.
      Early market access of cancer drugs in the EU.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martinalbo J.
        • Bowen D.
        • Camarero J.
        • Chapelin M.
        • Démolis P.
        • Foggi P.
        • et al.
        Early market access of cancer drugs in the EU.
        Ann Oncol. 2016; 27: 96-105
      1. Italian Medicines Agency, AIFA. Web site: http://www.agenziafarmaco.gov.it/it/content/normativa-di-riferimento-sperimentazione-clinica

        • Messori A.
        • Fadda V.
        • Maratea D.
        • Trippoli S.
        An Italian controversy: immediate availability of new anti-cancer agents before price negotiation by the national Medicines Agency.
        BMJ. 11 July 2013; (url http://www.bmj.com/content/346/bmj.f3634/rr/653476)
      2. Drugs included in the 648/96 list. Web site: http://www.agenziafarmaco.gov.it/sites/default/files/elenco_farmaci_MR_l648_16.11.2015.pdf

        • Fadda V.
        • Maratea D.
        • Trippoli S.
        • Messori A.
        Comparison between real prices and value-based prices of innovative drugs.
        Date: December 2010
        (Available at:) (Last accessed: 11/07/2013)
        • Matter-Walstra K.
        • Braun R.
        • Kolb C.
        • Ademi Z.
        • Dummer R.
        • Pestalozzi B.C.
        • et al.
        A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
        Br J Dermatol. 2015; 173: 1462-1470
      3. Italian registry on ruxolitinib. Web site: http://www.agenziafarmaco.gov.it/sites/default/files/Jakavi_Scheda_AIFA_02.01.2015.zip

        • Verstovsek S.
        • Mesa R.A.
        • Gotlib J.
        • Levy R.S.
        • Gupta V.
        • DiPersio J.F.
        • et al.
        A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
        N Engl J Med. 2012; 366: 799-807
        • Harrison C.
        • Kiladjian J.J.
        • Al-Ali H.K.
        • Gisslinger H.
        • Waltzman R.
        • Stalbovskaya V.
        • et al.
        JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
        N Engl J Med. 2012; 366: 787-798
        • Wade R.
        • Rose M.
        • Neilson A.R.
        • Stirk L.
        • Rodriguez-Lopez R.
        • Bowen D.
        • et al.
        Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
        PharmacoEconomics. 2013; 31: 841-845